HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masand, P. S. Search for Related Content PubMed PubMed Citation Articles by Masand, P. S.

PRAKASH S. MASAND, M.D., is Consulting Professor of Psychiatry and Behavioral Medicine, Duke University Medical Center, Box 3391 Med Ctr, Durham, NC 27710 (prakash.masand{at}duke.edu).

Purpose. Pharmacology of atypical antipsychotics and the clinical implications are reviewed. Summary. Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. Conclusion. Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders. Index terms: Antipsychotic agents; Compliance; Drugs; Mechanism of action; Mental disorders; Patients; Toxicity

 

This article has been cited by other articles:

				T. V. Nguyen Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients Am. J. Health Syst. Pharm., June 15, 2009; 66(12): 1101 - 1104. [Abstract] [Full Text] [PDF]

				K. Venkova, W. Mann, R. Nelson, and B. G.-V. Meerveld Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 1110 - 1116. [Abstract] [Full Text] [PDF]

				E. R. Viscusi, T. J. Gan, J. B. Leslie, J. F. Foss, M. D. Talon, W. Du, and G. Owens Peripherally Acting Mu-Opioid Receptor Antagonists and Postoperative Ileus: Mechanisms of Action and Clinical Applicability Anesth. Analg., June 1, 2009; 108(6): 1811 - 1822. [Abstract] [Full Text] [PDF]

				M. Heung, B. A Mueller, and J. H Segal Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease Ann. Pharmacother., February 1, 2009; 43(2): 276 - 282. [Abstract] [Full Text] [PDF]

				J. L Crandon, J. L Kuti, R. N Jones, and D. P Nicolau Comparison of 2002-2006 OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance Ann. Pharmacother., February 1, 2009; 43(2): 220 - 227. [Abstract] [Full Text] [PDF]

				M. R. Nuwer, G. J. Esper, P. D. Donofrio, J. P. Szaflarski, G. L. Barkley, and T. R. Swift Invited Article: The US health care system: Part 1: Our current system Neurology, December 2, 2008; 71(23): 1907 - 1913. [Abstract] [Full Text] [PDF]

				N. L. Metzger, K. E. Francis, and S. A. Voils A Comparative Review of Erythropoiesis Stimulating Agents Journal of Pharmacy Practice, December 1, 2008; 21(6): 424 - 430. [Abstract] [PDF]